Abstract. Glucagon-like peptide 1 (GLP-1) induces insulin secretion and proliferation of pancreatic β-cells, and inhibits their apoptosis through the GLP-1 receptor (GLP-1R), thus providing a foundation for using GLP-1-based therapies for the treatment of type 2 diabetes. However, doubts have emerged regarding the drug safety of these therapies. We investigated the potential role of GLP-1R in pancreatic ductal adenocarcinoma (PDAC). GLP-1R expression was semi-quantitatively evaluated by immunohistochemistry in 48 PDAC samples, and its correlations with clinicopathological features were investigated. CFPAC-1 cells were used for GLP-1R knockdown to evaluate its effects on cell proliferation, migration and invasion. GLP-1R expression was positive in 23 tumors and negative in 25 tumors. No correlations were found between GLP-1R expression status and clinicopathological characteristics. Furthermore, GLP-1R expression status did not affect the patient prognosis (P=0.74). The majority of lymph node metastases (11 of 15 samples examined; 73%) were positive for GLP-1R expression. Immunoreactivity for GLP-1R was also noted in sites of perineural and lymphovascular invasion. GLP-1R knockdown significantly reduced the proliferation, migration and invasion of CFPAC-1 cells (P<0.05). In conclusion, although GLP-1R is not an independent prognostic factor in PDAC patients, it appears to have some implications for PDAC metastatic ability.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease that frequently presents in an advanced stage with distant metastases due to a late diagnosis. Furthermore, few advances have been achieved in terms of therapeutic strategies for PDAC, thus patient survival remains at very low levels (4% at 5 years after diagnosis) (1) . For these reasons, it is essential to make progress in understanding the biological behavior of the disease, in parallel with making headway in its diagnosis and therapeutic strategies.
G-protein-coupled receptors (GPCRs) comprise an extensive family of cell-surface receptors involved in several cellular actions, and are the targets of approximately half of the medications available nowadays (2, 3) . Glucagon-like peptide 1 (GLP-1) receptor (GLP-1R), a member of the GPCR family, is involved in the so-called GLP-1-based therapies for the treatment of type 2 diabetes mellitus. It has been reported that treatment with the GLP-1R agonist exendin-4 did not affect the proliferation or survival of human pancreatic cancer cell lines (4) , while other authors reported that treatment with the GLP-1R agonist liraglutide had an antitumorigenic effect on human pancreatic cancer cells in vitro and in vivo (5, 6) . Regardless of these studies, continuing controversies have arisen that associate GLP-1-based therapies with high risks for the development of pancreatitis and pancreatic malignancies (7) (8) (9) (10) (11) (12) (13) (14) .
GLP-1R is a regulatory peptide receptor, and regulatory peptide receptors can be expressed in diverse human cancers (15) , and thus are considered useful for diagnostic imaging (due to the high receptor density in tumor tissues) and for radiation therapy when possible; both notable and promising clinical strategies.
We recently discussed the possible relationship between GLP-1R and the malignant behavior of pancreatic neuroendocrine tumors (PNETs), and the use of GLP-1R for the diagnosis of these tumors, as well as in therapeutic strategies for hormonal syndrome and in advanced cases with metastases (16) . Despite studies concerning the effects of GLP-1 agonists on pancreatic cancer cells (4) (5) (6) , to our knowledge, there is no information regarding the activity of GLP-1R itself in pancreatic cancer cells. The aims of the present study were to assess GLP-1R expression in primary and metastatic sites of PDAC by immunohistochemical analysis and to examine whether GLP-1R knockdown affected pancreatic cancer cell function. 
Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer

Evaluation of GLP-1R expression.
There is general agreement that islets of Langerhans have a high density of GLP-1R (5, 13, (17) (18) (19) . For this reason, and similar to a previous study (13) , we used GLP-1R expression in these islets as an internal positive control for the immunohistochemical analysis. GLP-1R expression was evaluated as previously described (16, 20) . Briefly, samples were analyzed using an intensity score (IS) that compared the levels of staining in tumor cells and islets of Langerhans ( Fig. 1A and E) and graded them as follows: 0, no staining (Fig. 1A) ; 1, weak staining (Fig. 1B) ; 2, moderate staining (Fig. 1C) ; and 3, strong staining (Fig. 1D) . A proportional score (PS) was also used to grade the samples as follows: 0, staining in <10% of the area; 1, staining in ≥10% but <30% of the area; 2, staining in ≥30% but <50% of the area; 3, staining in ≥50% but <80% of the area; and 4, staining in ≥80% of the area. Quantitative real-time reverse transcription-polymerase chain reaction. Total RNA was extracted from cultured cells using a High Pure RNA Isolation kit and DNase I (both from Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. RNA was quantified by its absorbance at 260 nm and evaluated for its purity by the 260/280 absorbance ratio using a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Waltham, MA, USA). Quantitative realtime reverse transcription-polymerase chain reaction (qRT-PCR) was performed using a QuantiTect SYBR-Green RT-PCR kit (Qiagen, Venlo, The Netherlands) and a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). Briefly, each reaction mixture was initially incubated for 30 min at 50˚C to allow RT. The PCR initial activation step was performed at 95˚C for 15 min to activate the polymerase, followed by 40 three-step cycles of 15 min at 94˚C, 30 min at 55˚C and 30 min at 72˚C. The primers (Sigma-Aldrich) used were: GLP-1R forward, 5'-tctgcatcgtggtatccaaa-3' and GLP-1R reverse, 5'-cttggcaagtctgcatttga-3'; 18S forward, 5'-gtaacccgttgaaccccatt-3' and 18S reverse, 5'-ccatccaatcggtagtagccg-3'. Data were calculated as the relative GLP-1R expression levels normalized by the 18S rRNA levels. All samples were run in duplicate or triplicate at least three times.
Western blot analysis. Cells were lysed in PRO-PREP™ (iNtRON Biotechnology, Seongnam, Korea). Cell lysate proteins (5-15 µg) were fractionated in 4-15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels (Bio-Rad Laboratories) and transferred to polyvinylidene difluoride membranes (Trans-Blot ® Turbo™; Bio-Rad Laboratories). The membranes were incubated overnight at 4˚C with anti-GLP-1R (ab39072; dilution, 1 µg/ml; Abcam, Cambridge, UK) or anti-β-actin (sc-81178; dilution, 1:2,500) antibodies, and then probed with secondary antibodies conjugated with horseradish peroxidase (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunoreactive bands were analyzed using an ECL detection system (GE Healthcare, Buckinghamshire, UK) and chemiluminescence was detected using a ChemiDoc™ XRS (Bio-Rad Laboratories).
GLP-1R silencing by small interfering RNAs.
For receptor silencing, we used the following small interfering RNAs (siRNAs; all purchased from Qiagen): GLP-1R 4 sense, 5'-gga acuccaacaugaacuatt-3' and GLP-1R 4 antisense, 5'-uaguucaugu uggaguucctg-3'; GLP-1R 5 sense, 5'-ggcucguucgugaauguc att-3' and GLP-1R 5 antisense, 5'-ugacauucacgaacgagcctg-3'. A negative control siRNA (siControl; Qiagen) was used to verify the knockdown specificity. Transfections of CFPAC-1 cells (up to passage 8) were performed by electroporation using a Nucleofector™ device (Lonza, Cologne, Germany) in triplicate. Cells (1.7-2x10 6 ) were centrifuged at 2,000 x g for 1 min, and the supernatant was discarded. Next, the cells were Cell proliferation assay. Cell proliferation was evaluated by measuring the fluorescence intensity of propidium iodide (PI) as previously described (23) . Transfected CFPAC-1 cells were suspended in DMEM without phenol red supplemented with 10% FBS, and seeded at a density of 2x10 4 cells/well in 24-well cell culture plates (BD Falcon, BD Biosciences, Franklin Lakes, NJ, USA). After 24 h of culture, the medium was changed to fresh serum-free medium for 24 h of culture under serum starvation. The following day, the medium was replaced with DMEM without phenol red supplemented with 1% FBS, and evaluated for cell proliferation by the PI assay. Briefly, PI (30 µM) and digitonin (600 µM) were added to each well and the fluorescence intensity was measured using a multimode microplate reader (Infinite F200; Tecan, Grödig, Austria) with 535-nm excitation and 620-nm emission filters. A separate well with the same medium but no cells was used to obtain a baseline PI signal as a control, and the difference between each sample well and the control well was evaluated. Cell proliferation was defined relative to the cell number measured at the beginning of the experiment (day 0). All experiments were performed in triplicate wells and repeated at least three times.
Invasion and migration assays. Invasion of transfected CFPAC-1 cells was assessed by counting the numbers of cells that invaded through Matrigel-coated Transwell chambers with 8-µm pore size membranes (BD Biosciences). The Transwell inserts were coated with 20 µg/well BD Matrigel™ (BD Biosciences). Each group of transfected cells (1x10 5 ) was suspended in 250 ml of DMEM containing 1% FBS and placed in the upper chamber. The upper chamber was then placed in the well of a 24-well culture dish containing 750 ml of DMEM with 10% FBS. In addition, cellular migration was assessed using uncoated Transwell inserts. After 24 h of incubation, the invading and migrating cells were fixed with 70% ethanol and stained with hematoxylin and eosin (H&E). The cell numbers were counted under a light microscope in five random fields at a magnification of x200 for migration, and in one random field at a magnification of x100 for invasion. The results were expressed as the mean numbers of counted cells/field. Each experiment was carried out in quadruplicate wells and repeated three times.
Statistical analysis. Statistical analyses were carried out using JMP 10 for Windows software (SAS Institute, Inc., Cary, NC, USA). Survival was evaluated from the time of surgery, with death as the end point. The cumulative survival rate was determined by Kaplan-Meier analysis. In cellular experiments, data are expressed as means ± SD. Differences between two groups were estimated by the Student's t-test or the χ 2 test. Experiments were repeated at least three times. Differences were considered significant for values of P<0.05.
Results
Evaluation of GLP-1R in pancreatic cancer.
Immunohistochemical evaluation of GLP-1R was performed in 48 PDAC specimens from 48 patients, comprising 22 women and 26 men with a median age of 64 years (range, 36-82 years) ( Table I) . The results revealed 23 tumors (48%) with positive-GLP-1R expression and 25 tumors (52%) with negative-GLP-1R expression (Table I) . A noteworthy element was the presence of GLP-1R-positive tumor cells in invasive localization areas, such as perineural invasion, lymph vessel invasion and vascular invasion (Fig. 1F-H) . Table II shows the associations between GLP-1R expression and the clinicopathological features of the 48 patients. There were no significant associations between the receptor expression status and the clinicopathological features. Similarly, the overall survival rates showed no significant difference between the positive and negative groups for GLP-1R expression (P=0.74; Fig. 2 ).
GLP-1R expression and its correlations with clinicopathological features and the survival analysis.
GLP-1R analysis in metastatic sites
. From the total of 42 patients with lymph node metastasis (Table I) , 15 metastatic lymph node samples were randomly selected and immunohistochemically evaluated for the expression of GLP-1R. Most of the samples (11 of 15; 73%) showed positive staining for GLP-1R (Table III, Fig. 3A) , while the remaining four samples (27%) were classified as GLP-1R-negative (Table III , Fig. 3B ).
Although there was a correlation between GLP-1R expression in the primary site and the metastatic site in 13 samples (i.e. positive-positive or negative-negative), two samples with negative expression in the primary sites showed positive-GLP-1R expression in the metastatic sites.
GLP-1R knockdown has a positive impact on the malignant behavior of CFPAC-1 pancreatic cancer cells.
First, we investigated the presence of GLP-1R expression in several pancreatic cancer cell lines as well as in normal pancreatic cells by qRT-PCR and western blot analysis (Fig. 4A) . Next, for knockdown experiments, the cell line CFPAC-1 was selected due to its high receptor expression at both the mRNA and protein levels. Knockdown efficacy was verified by qRT-PCR and western blot analysis at 48 h post-transfection (Fig. 4B) . We found that GLP-1R knockdown significantly decreased the proliferation of CFPAC-1 cells after 4 days of culture when using siGLP-1R 4, and after 5 days of culture when using both siGLP-1R 4 and siGLP-1R 5, as compared with siControl (Fig. 4C) . Similarly, the receptor knockdown significantly decreased the cell migration and invasion compared with siControl (Fig. 4D ).
Discussion
We analyzed the expression of GLP-1R in 48 surgically resected PDAC specimens, and examined its relationships with several clinicopathological factors. The immunohistochemical analysis procedure was the same as that used in our previous study (16) , in which we examined GLP-1R expression in PNETs and found no significant associations between the receptor expression status and several clinicopathological characteristics. Similar to our previous study, GLP-1R expression was not found to be a predictive factor for survival in PDAC patients. The receptor expression showed dissimilar levels (at both the mRNA and protein levels) even among pancreatic cancer cells, indicating that the receptor expression was markedly variable from one cell to another (heterogeneity), and that even if there was a relationship between GLP-1R and tumor behavior, this was lost when the samples were evaluated together. We evaluated samples of metastatic lymph nodes, and found that most of these samples were GLP-1R-positive (11 of 15 samples; 73%). It was interesting that 13 samples showed a direct correlation for GLP-1R expression between the primary site and its metastatic counterpart, while the remaining two samples with negative GLP-1R expression in the primary site showed positive GLP-1R expression in the metastatic site, suggesting that cells expressing GLP-1R may have an increased metastatic ability. In other words, even though the expression status in the primary site was judged to be negative, there could be a minor compartment of GLP-1R-positive cells arising through tumor heterogeneity, and these cells may be able to metastasize to lymph nodes. To our knowledge, this is the first study to reveal the expression of GLP-1R in metastatic samples of PDAC, a finding to consider given the negative impact that metastases have on patient survival. Additional investigations of GLP-1R expression in other metastatic sites, such as the liver and lung are warranted. Although a previous study described an immunohistochemical analysis of GLP-1R in PDAC and its relationships with several clinicopathological factors (5), the present study involved a larger number of patients for immunohistochemical evaluation of the receptor, and included samples from metastatic sites. In the previous study, Zhao et al (5) found that negative GLP-1R expression in PDAC samples was associated with a larger tumor diameter (this information was additionally presented by the same authors in a second study) (6), conjointly with lymphatic metastasis and a poorer overall survival compared with patients with GLP-1R-positive tumors. We think that the differences compared with our findings exceed the mere facts of using antibodies from different commercial brands or different sample numbers and could possibly arise through methodological differences in the immunohistochemical evaluations.
As we observed GLP-1R-positive tumor cells in invasive areas as well as in metastatic lymph nodes, we questioned whether the receptor influences the metastatic ability of To address this question, we performed siRNA experiments to achieve receptor knockdown, and found that GLP-1R knockdown decreased the proliferation of CFPAC-1 cells, and also induced noticeable decreases in the cell migration and invasion abilities. To the best of our knowledge, this is the first study to disclose that GLP-1R silencing decreases the malignant behavior of PDAC cells, and these results may support our immunohistochemical findings, wherein metastatic lymph nodes were frequently GLP-1R-positive. Taken together, the data obtained in the present study suggest that GLP-1R plays a role in the metastatic potential of PDAC cells. In the absence of any treatment, we hypothesized that GLP-1R may be functioning without a ligand to mediate its activation; for example, through autophosphorylation with the consequent triggering of cellular signals. Alterations in GPCRs have been described and linked to carcinogenesis (3, 24) , and thus GLP-1R may not be an exception. Notably, at the beginning of the experiments using CFPAC-1 cells with GLP-1R knockdown, a dose of 10% FBS in the medium was used, yet the results were not significant. Subsequently, we decided to reduce the FBS concentration to 1%, resulting in significant differences under this condition. In view of this situation, and since the sequences of the GLP-1 peptide are quite similar among mammals (25), our hypothesis was that traces of bovine GLP-1 in the FBS could be stimulating some GLP-1Rs still present in the cell membrane, thereby interfering with the results. Using western blot analysis and ELISA, we searched for the presence of bovine GLP-1 in the FBS, but the results were negative (data not shown). Nevertheless, we cannot totally confirm the absence of GLP-1 in the FBS, or the possible presence of another metabolite that functions as a receptor agonist. In our previous study (16) , we reported that GLP-1 treatment increased the proliferation as well as the migration of the insulinoma cell line MIN6, and numerous studies have associated GLP-1-based therapies with pancreatic disease in recent years (7) (8) (9) (10) (11) (12) (13) (14) 17) . Moreover, using mutant GLP-1Rs, Ge et al (26) described that even with a mutation of the putative signal sequence, ligand binding to the mutant receptor was observed with conserved cAMP production. In summary, although an aberrant GLP-1R presented an agonist-independent functionality as the siRNA data suggest, an agonist-dependent functionality cannot be discarded. One limitation of the present study is that the downstream signals related to GLP-1R knockdown were not investigated. However, the in vitro data firmly demonstrated that GLP-1R silencing decreased the malignant ability of PDAC cells. Further experiments will be necessary to clarify the cell signals involved in this hypothetical ligand-independent receptor process.
In our previous study (16) , we discussed the potential use of GLP-1R for the diagnosis and treatment of metastatic PNETs. In a similar way, we can also think of GLP-1R as a molecular target not only for the treatment of PDAC, but also as a diagnostic molecular marker for metastatic PDAC, e.g., its utilization in scintigraphy techniques. However, given the results described in the present study, wherein GLP-1R promoted the metastatic potential of PDAC cells, it is useful to mention that GLP-1R showed an excellent response to radiolabeled antagonist binding (19) . The latter observation posits that the hypothetical use of a radiolabeled antagonist for the diagnosis of advanced PDAC would not involve undesired side-effects, unlike the case for many agonists. Although GLP-1R showed minimal antagonist-induced internalization compared with agonists (27) , receptor internalization is considered to be a very attractive feature in terms of retention of radioactivity for radionuclide therapy application (28) .
In conclusion, although GLP-1R expression was not found to be an independent prognostic factor in PDAC patients by immunohistochemical analysis, it appears to have some implications for PDAC metastatic ability. It is necessary to monitor the long-term safety of GLP-1 mimetic therapies, as well as to examine GLP-1R as a possible molecular target for the diagnosis and treatment of advanced PDACs.
